Baiaotai\'s announcement on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Baiaotai\'s announcement on participating in the 2024 Investor Online Group Reception Day in Guangdong
Biotech voluntarily disclosed the notice of approval for dupriumab injection (BAT2406) for drug clinical trials
Biotech voluntarily disclosed the notice of approval for clinical trials of BAT8006 combined with bevacizumab
China International Finance Co., Ltd.'s verification opinion on the temporary supplementation of working capital using a portion of idle raised funds by Bio-Thera Solutions, Ltd.
Bio-Thera Solutions Announcement on the Temporary Supplement of Working Capital Using Part of the Idle Fund Raised
Bio-Thera Solutions 's semi-annual assessment report on the special action plan to improve quality and efficiency and return to the report in 2024.
Bio-Thera Solutions 2024 Semi-Annual Report
Bio-Thera Solutions special report on the deposit and actual use of funds for the first half of 2024.
Announcement of the resolution of the 15th meeting of the second board of supervisors of Bio-Thera Solutions
Bio-Thera Solutions' Summary of 2024 Half-Yearly Report
Bio-Thera Solutions Announcement on the Return of Idle Fund Raised for Temporary Working Capital Supplement.
Bio-Thera Solutions' Announcement on the Approval of Avzivi (Bavencio Injection) by the European Commission
Bio-Thera Solutions,: Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
Bio-Thera Solutions voluntarily disclosed the announcement about milestone payment received for the authorization and commercialization agreement signed with Hikma Pharmaceuticals USA Inc. regarding BAT2206 (ustekinumab injection).
Bio-Thera Solutions voluntarily disclosed the announcement about the acceptance of the application for the marketing authorization of BAT2206 (Ustekinumab Injection) by the US FDA and the European Medicines Agency (EMA).
Bio-Thera Solutions Investor Event Record (July 18, 2024)
Bio-Thera Solutions Investor Event Record (July 4, 2024)
Bio-Thera Solutions voluntarily announced the progress of receiving the first payment for the BAT2506 (Golimumab injection) licensing and commercialization agreement with STADA.
No Data